Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07318389 · ClinicalTrials.gov registry record · Early Phase 1
ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer
A Early Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Not yet
- Registry status
- Early Phase 1
- Development phase
- 100
- Enrollment target
NCT07318389: Clinical Trial Early Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT07318389 is a Early Phase 1 study that has not yet begun recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 100 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (89% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07318389, a Early Phase 1 study, has not yet begun recruiting, sponsored by M.D. Anderson Cancer Center.
- NOT YET RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 100 participants
- Enrollment target
Study Summary
To find out if certain drug/therapy combinations that are targeted to individual patients based on characteristics of their disease types may help to control the disease.
Primary Outcome
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Interventions
- DRUG Bevacizumab
- DRUG Cetuximab
- OTHER SOC (Standard of care)
- DRUG FOLFIRI
- DRUG Panitumumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2026-06-10 |
| Est. Completion | 2029-11-14 |
| Phase | Early Phase 1 |
What is known before NCT07318389 opens enrollment
NCT07318389 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (89% higher).
The record links to 0 conditions, and to 5 interventions - of which Bevacizumab is the first listed.
NCT07318389 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07318389 about?
NCT07318389 is a clinical study titled "ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer". To find out if certain drug/therapy combinations that are targeted to individual patients based on characteristics of their disease types may help to control the disease.
What is the current status of trial NCT07318389?
This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 100 participants. The study started on 2026-06-10. Estimated completion is 2029-11-14.
What interventions are being tested in trial NCT07318389?
The interventions under investigation include: Bevacizumab (DRUG), Cetuximab (DRUG), SOC (Standard of care) (OTHER), FOLFIRI (DRUG), Panitumumab (DRUG).
Who is sponsoring clinical trial NCT07318389?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07318389's enrollment target sits among peer trials
100 184th of 2000 higher than 1,782 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI